A blood-flow idea that seemed plausible
Sildenafil’s story is often told as a success story of vascular medicine.
It improves erectile function by enhancing nitric-oxide signaling and relaxing smooth muscle in blood vessels. That same vascular logic led researchers to ask a very different question: could sildenafil help pregnancies complicated by severe fetal growth restriction?
The hypothesis sounded reasonable. If the placenta was not delivering enough oxygen and nutrients, perhaps a vasodilator could improve uteroplacental blood flow and help the fetus grow.
That is how sildenafil moved, experimentally, from male sexual medicine into maternal-fetal medicine.
The trial result was not reassuring
The Dutch STRIDER trial tested maternal sildenafil in women with severe early-onset fetal growth restriction. The result did not support the hoped-for benefit.
In the JAMA Network Open report, perinatal mortality or major neonatal morbidity was not reduced. The outcome occurred in 60.2% of offspring in the sildenafil group and 54.2% in the placebo group. More concerning, neonatal pulmonary hypertension occurred in 18.8% of neonates exposed to sildenafil, compared with 5.1% in the placebo group. (JAMA Network)
Regulators took notice. The UK MHRA warned in 2018 that sildenafil was not authorized for intrauterine growth restriction and that the STRIDER trial had been prematurely discontinued because of higher persistent pulmonary hypertension of the newborn and neonatal mortality in the sildenafil arm. (GOV.UK)
Why this matters for Fildena
A search such as Fildena sildenafil fetal growth restriction trial shows a side of sildenafil that ordinary ED pages rarely discuss.
The same molecule can make sense in one vascular setting and fail in another.
That is the lesson. Mechanism is not destiny. A drug that relaxes blood vessels in one context does not automatically improve outcomes in every disease involving blood flow.
Pregnancy, the placenta, fetal circulation, and newborn pulmonary vessels are not interchangeable with erectile tissue.
The off-label trap
The fetal-growth-restriction story is a warning about off-label enthusiasm.
Medicine often begins with a plausible mechanism. Sometimes that mechanism becomes a useful treatment. Sometimes it does not. Sometimes it creates harm that was not obvious from the theory.
Sildenafil in fetal growth restriction looked scientifically attractive because it targeted blood-flow biology. But controlled trials forced a harder conclusion: the hoped-for neonatal benefit did not appear, and safety concerns emerged. A later review of prenatal sildenafil noted that the STRIDER randomized trial was halted after interim analysis because of futility and higher rates of persistent pulmonary hypertension and mortality in sildenafil-exposed neonates. (PubMed)
That is why clinical trials matter.
They test not only whether a drug can do something, but whether doing that thing actually helps patients.
The practical takeaway
Fildena should not be understood as a simple “blood-flow enhancer.”
Sildenafil is a real pharmacological tool. In some settings, it is useful. In others, it may be inappropriate, ineffective, or risky. The fetal-growth-restriction trials show that even a well-known drug can produce unexpected outcomes when moved into a new biological system.
The safest question is not only “does sildenafil work?”
The better question is: for whom, for what condition, at what dose, and under what evidence?
Disclaimer
This article is for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Sildenafil or any erectile dysfunction medication should be used only under the guidance of a qualified healthcare professional.
References
Pels A, et al. Maternal sildenafil vs placebo in pregnant women with severe early-onset fetal growth restriction; neonatal pulmonary hypertension signal reported. (JAMA Network)
UK MHRA Drug Safety Update: sildenafil not authorized for intrauterine growth restriction; STRIDER trial prematurely discontinued after safety concerns. (GOV.UK)
Terstappen F, et al. Prenatal sildenafil in fetal growth restriction and neonatal oxygenation; STRIDER halted for futility and higher pulmonary hypertension/mortality rates. (PubMed)
STRIDER Consortium comment advising clinicians to stop prescribing sildenafil for fetal growth restriction. (PubMed)
